相关实验视频

Updated: Jul 4, 2025

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Transcatheter Pulmonary Valve Replacement from Autologous Pericardium with a Self-Expandable Nitinol Stent in an Adult Sheep Model

Published on: June 8, 2022

在心力衰竭中进行过导管大动脉置换

Puja B Parikh¹, Michael Mack², Gregg W Stone³

¹Department of Medicine, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA.

European journal of heart failure

|February 1, 2024

概括

过导管大动脉置换 (TAVR) 改善了严重大动脉狭窄和心力衰竭的患者的治疗结果. 这次审查详细介绍了TAVR的细节.

科学领域:

心脏病学心脏病学
心血管外科心血管外科
心脏衰竭管理的管理

背景情况:

严重的大动脉狭窄 (AS) 可能导致心力衰竭 (HF),历史上与预后不佳有关.
超导管大动脉置换 (TAVR) 现在是AS患者的首要治疗方法.
TAVR提供了即时的血液动力学益处,改善了HF患者的心脏结构,存活率和生活质量.

研究的目的:

审查TAVR对心力衰竭患者结局的影响.
专注于特定的HF人群:左心室缩功能障碍,急性HF和右心室缩功能障碍.
识别与HF在AS中的TAVR相关的知识差距和未来研究方向.

主要方法:

对评估大动脉狭窄和心力衰竭患者TAVR研究的文献综述.
血液动力学变化,左心室重塑和TAVR后的生存数据的分析.
对不同HF表型的TAVR结果的证据综合.

主要成果:

TAVR显示出显著的血液动力学益处和左心室结构的改善.
接受TAVR治疗的AS和HF患者的死亡率和生活质量有所提高.
在特定的高压子组 (LV缩功能障碍,急性高压,RV缩功能障碍) 的结果需要进一步调查.

结论:

TAVR是心力衰竭严重AS患者的有效治疗方法,改善了血液动力学和长期结果.
需要进一步的研究来澄清预后因素和最佳的TAVR时间,特别是在不太严重的AS和特定的HF表现.
TAVR代表了管理心力衰竭复杂的AS的范式转变.

关键词:

大动脉狭窄症大动脉狭窄症喷射分数的喷射分数是什么心脏衰竭是因为心脏衰竭.通过导管进行大动脉干预.通过导管更换大动脉门.

更多相关视频

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Technique and Patient Selection Criteria of Right Anterior Mini-Thoracotomy for Minimal Access Aortic Valve Replacement

Published on: March 26, 2018

Implantation of Total Artificial Heart in Congenital Heart Disease

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

相关概念视频

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...

Pathophysiology of Heart Failure

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...